Loading...

ERNA ERNEXA THERAPEUTICS INC Company Mergers 8-K Filing

RNX

RN

ERNEXA THERAPEUTICS INC

(ERNA)

2024 8-K

Show Summary

Summary

Equity Offerings

Increase in authorized shares

Securities Agreement

Promissory Note Issued

Promissory Note Issued

Annual Meeting Notice

Nasdaq Compliance Notice

Nasdaq Compliance Notice

Private Placement

New License Agreement

Nasdaq Compliance Issue

Annual Meeting Notice

Delisting Notice

Appointment of Director

Private Placement of Conver...

Promissory Note Issued

License Agreement

Appointment of Dr. James Br...

Appointment of Director

Investor Presentation

Equity Offerings

Annual Meeting Voting Results

Appointment and Resignation

Asset Purchase Agreement

Financial Results Announcement

Exclusive License Agreement...

Resignation of CMO

Delisting and Management Ap...

External Links:

Eterna Therapeutics Inc. entered into a new Exclusive License and Collaboration Agreement with Factor Bioscience, replacing previous agreements, allowing Eterna to develop technology for cancer and other diseases, with payments totaling $208,333 monthly for the first year and additional costs.

AI Assistant

ERNEXA THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.